Levels of glycosaminoglycans in the cerebrospinal fluid of healthy young adults, surrogate-normal children, and Hunter syndrome patients with and without cognitive impairment
In mucopolysaccharidoses (MPS), glycosaminoglycans (GAG) accumulate in tissues. In MPS II, approximately two-thirds of patients are cognitively impaired. We investigated levels of GAG in cerebrospinal fluid (CSF) in different populations from four clinical studies (including NCT00920647 and NCT01449...
Main Authors: | Christian J. Hendriksz, Joseph Muenzer, Adeline Vanderver, Jonathan M. Davis, Barbara K. Burton, Nancy J. Mendelsohn, Nan Wang, Luying Pan, Arian Pano, Ann J. Barbier |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2015-12-01
|
Series: | Molecular Genetics and Metabolism Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2214426915300513 |
Similar Items
-
The Interplay of Glycosaminoglycans and Cysteine Cathepsins in Mucopolysaccharidosis
by: Alexis David, et al.
Published: (2023-03-01) -
Long-term experience with idursulfase beta (Hunterase) in two adolescent patients with MPS II: A case series
by: Mei-Yan Chan, et al.
Published: (2023-09-01) -
Mucopolysaccharidoses in northern Brazil: Targeted mutation screening and urinary glycosaminoglycan excretion in patients undergoing enzyme replacement therapy
by: Gustavo M. Viana, et al.
Published: (2011-01-01) -
Caregiver experiences and observations of intrathecal idursulfase-IT treatment in a phase 2/3 trial in pediatric patients with neuronopathic mucopolysaccharidosis II
by: Karen S. Yee, et al.
Published: (2024-03-01) -
Clinical investigator perspectives on patient outcomes in children with neuronopathic mucopolysaccharidosis II during intrathecal idursulfase-IT treatment
by: Karen S. Yee, et al.
Published: (2024-04-01)